The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-08

Study Completion Date

2023-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determination of Risk Factors of Shoulder Pathologies in Parkinson Disease

NCT06456840

Parkinson Disease Shoulder Pain

NOT_YET_RECRUITING

Upper Extremity Functional Skills in Patients With Parkinson Disease (pwPD)

NCT07180004

PARKINSON DISEASE (Disorder) Upper Extremity Muscle Strength Development +1 more

COMPLETED

The Relationship Between Upper Extremity Function and Balance and Functional Mobility in Parkinson's Disease

NCT06591975

Parkinson Disease

RECRUITING

The Effect of Proprioceptive Neuromuscular Facilitation on Trunk Mobility, Gait, Fear of Falling, and Quality of Life in Individuals Diagnosed With Parkinson's Disease

NCT07327645

PARKINSON DISEASE (Disorder) Proprioceptive Neuromuscular Facilitation Fear of Falling +3 more

COMPLETED NA

Postural Sway of Trunk and Upper Extremity Functional Skills in Atient With Parkinson Disease (pwPD)

NCT07182487

PARKINSON DISEASE (Disorder) Postural Instability Trunk Stability Impairment +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. Involvement of nigrostriatal dopaminergic neurons is associated with the motor manifestations of the disease. The most common of these symptoms are; resting tremor, bradykinesia, rigidity and balance disorder. However, non-motor symptoms related to the involvement of nervous system structures other than the dopaminergic nigrostriatal system can be observed in PD. However, due to the predominance of motor symptoms in PD, it took many years to notice cognitive changes. Traditionally, cognitive impairments in PD have been expected to occur in the advanced stages of the disease. However, cognitive impairments in the early stages are reported in approximately 30-35% of patients. Cognitive dysfunction is defined in PD, ranging from mild impairments in certain cognitive domains to severe dementia. Cognitive impairment primarily affects executive and visuospatial functions, and memory is secondarily affected.

Executive functions are higher cognitive processes that use and modify information from many cortical sensory systems in the fore and hindbrain areas to modulate and teach behavior. The frontal cortex, especially the prefrontal cortex and its striatal connections are very important neuroanatomical regions for executive functions. The relationship between the effects of cognition and motor performance and parameters in groups such as the elderly, PD and Alzheimer's patients in which these centers are affected has been an issue that has attracted the attention of many researchers. Most of the studies have focused on the lower extremity performance of cognition. However , it has been reported that cognition has positive effects on upper extremity performance and early acquired upper extremity skills have positive effects on cognitive performance .

The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Cognitive Impairment Upper Extremity Problem Functional Disturbance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

patient and age-gender matched healthy groups

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient group

parkınson patient group

Group Type EXPERIMENTAL

clinical assessment

Intervention Type DIAGNOSTIC_TEST

clinical staging

healthy group

age-gender matched healthy group

Group Type OTHER

clinical assessment

Intervention Type DIAGNOSTIC_TEST

clinical staging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clinical assessment

clinical staging

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

modifiye hoehn yahr

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having a diagnosis of Parkinson's Disease.
* Not having hearing and vision problems.
* To be able to take the commands required for the manual dexterity tests.
* Agree to participate in the study.

Exclusion Criteria

* Having undergone musculoskeletal surgery for the upper extremity.
* Having vision and hearing problems.
* Having an additional disease that may affect cognitive tests.

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes